ESPR
Esperion Therapeutics, Inc. NASDAQ Listed Jun 26, 2013$3.15
-0.63%
vs $3.17
Mkt Cap $654.9M
52w Low $0.95
68.1% of range
52w High $4.18
50d MA $2.78
200d MA $3.02
P/E (TTM)
-28.6x
EV/EBITDA
15.7x
P/B
—
Debt/Equity
-1.8x
ROE
7.5%
P/FCF
-50.7x
RSI (14)
60.00
ATR (14)
$0.01
Beta
1.17
50d MA
$2.78
200d MA
$3.02
Avg Volume
11.0M
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
3891 Ranchero Drive · Ann Arbor, MI 48108 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.04 | -0.10 | -150.0% | 3.15 | +0.0% | -0.3% | -0.3% | +0.0% | -0.3% | +0.0% | — |
| Mar 10, 2026 | AMC | 0.23 | 0.22 | -4.3% | 2.70 | -0.7% | -4.1% | -4.6% | -1.2% | +10.2% | +0.7% | — |
| Nov 6, 2025 | AMC | -0.09 | -0.16 | -77.8% | 2.50 | +0.0% | +6.4% | +8.3% | +7.6% | -2.3% | -2.3% | — |
| Aug 5, 2025 | AMC | -0.17 | -0.02 | +88.2% | 1.62 | +0.6% | +18.5% | -5.7% | +3.3% | -1.1% | -3.2% | — |
| May 6, 2025 | AMC | -0.18 | -0.21 | -16.7% | 0.98 | +1.5% | -10.7% | +2.5% | -10.6% | +0.1% | -2.3% | — |
| Mar 4, 2025 | AMC | -0.14 | -0.10 | +28.6% | 1.77 | +0.6% | -6.8% | -3.6% | +6.3% | -6.5% | -1.9% | — |
| Nov 7, 2024 | AMC | -0.14 | -0.15 | -7.1% | 2.11 | -0.9% | +8.1% | +10.5% | -3.6% | -8.2% | -5.8% | — |
| Aug 12, 2024 | AMC | -0.15 | -0.05 | +66.7% | 1.84 | +1.1% | -2.2% | +3.3% | +5.9% | -0.5% | -3.1% | — |
| May 7, 2024 | AMC | 0.05 | 0.34 | +580.0% | 2.37 | -4.2% | -13.9% | +2.5% | +4.8% | +1.8% | -2.2% | — |
| Feb 27, 2024 | AMC | -0.53 | -0.50 | +5.7% | 2.90 | +0.7% | -11.4% | -2.3% | +1.6% | -4.3% | -1.6% | — |
| Nov 7, 2023 | AMC | -0.42 | -0.37 | +11.9% | 1.03 | +1.9% | -3.8% | -10.8% | +2.4% | +4.5% | +15.3% | — |
| Aug 1, 2023 | AMC | -0.63 | -0.46 | +27.0% | 1.69 | -3.6% | +5.9% | -8.4% | -0.6% | -2.5% | +1.9% | — |
| May 9, 2023 | TNS | -0.65 | -0.79 | -21.5% | 1.42 | +1.4% | +2.8% | +2.1% | +3.4% | +10.4% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | Citizens | Maintains | Market Outperform → Market Outperform | — | $2.47 | $2.56 | +3.6% | -1.2% | +10.2% | +0.7% | -7.4% | +3.6% |
| Mar 3 | Needham | Maintains | Buy → Buy | — | $3.27 | $3.12 | -4.6% | -11.0% | +0.0% | -4.8% | -1.8% | +11.8% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.83 | +2.9% | -3.3% | -5.6% | -1.2% | -2.0% | +5.3% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.17 | $1.15 | -1.7% | -6.8% | +0.9% | -2.7% | -2.8% | +2.9% |
| May 7 | Needham | Maintains | Buy → Buy | — | $0.98 | $0.99 | +1.5% | -10.7% | +2.5% | -10.6% | +0.1% | -2.3% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.88 | $0.89 | +1.0% | +4.4% | -1.4% | +5.8% | +4.1% | -1.5% |
| Apr 25 | Needham | Maintains | Buy → Buy | — | $0.88 | $0.89 | +1.0% | +4.4% | -1.4% | +5.8% | +4.1% | -1.5% |
| Apr 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $0.96 | $0.97 | +0.6% | -1.4% | -10.3% | +9.1% | +2.1% | -7.2% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $1.20 | $1.24 | +3.3% | -11.7% | -0.9% | -8.6% | +6.2% | -2.0% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.67 | $1.62 | -3.0% | -3.0% | +4.3% | +3.0% | -3.4% | -3.0% |
| Mar 5 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $1.77 | $1.78 | +0.6% | -6.8% | -3.6% | +6.3% | -6.5% | -1.9% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.58 | $1.65 | +4.4% | +12.0% | -6.8% | -3.6% | +6.3% | -6.5% |
| Feb 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.86 | $1.83 | -1.6% | -3.8% | +5.0% | -0.5% | -0.5% | +0.5% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.86 | $1.83 | -1.6% | -3.8% | +5.0% | -0.5% | -0.5% | +0.5% |
| Jan 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.20 | $2.20 | +0.0% | -5.5% | +1.0% | -5.2% | -2.0% | -3.1% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.20 | +0.0% | -5.5% | +1.0% | -5.2% | -2.0% | -3.1% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.16 | +0.5% | +2.3% | -5.5% | +1.0% | -5.2% | -2.0% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.17 | +0.0% | +7.8% | -2.6% | -1.8% | -1.3% | +2.3% |
| Dec 13 | Needham | Maintains | Buy → Buy | — | $2.55 | $2.18 | -14.5% | -11.8% | +3.6% | +5.6% | -12.2% | +0.5% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.18 | -14.5% | -11.8% | +3.6% | +5.6% | -12.2% | +0.5% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.69 | $2.72 | +1.1% | -5.2% | -11.8% | +3.6% | +5.6% | -12.2% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.10 | $3.05 | -1.6% | +4.8% | +12.6% | -8.7% | +4.2% | +10.1% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.78 | -0.7% | +10.7% | +4.8% | +12.6% | -8.7% | +4.2% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.59 | +0.8% | -1.2% | +10.2% | +10.7% | +4.8% | +12.6% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.13 | -0.9% | +12.1% | +0.0% | +2.5% | +2.0% | +2.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.11 | $2.09 | -0.9% | +8.1% | +10.5% | -3.6% | -8.2% | -5.8% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.61 | $1.61 | +0.0% | +13.0% | +7.7% | +10.2% | -5.6% | +1.5% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $1.84 | $1.86 | +1.1% | -2.2% | +3.3% | +5.9% | -0.5% | -3.1% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.02 | $1.86 | -7.9% | -8.9% | -2.2% | +3.3% | +5.9% | -0.5% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.31 | $2.49 | +7.8% | -3.9% | +5.4% | +0.0% | +0.9% | +3.8% |
| Jun 28 | Needham | Maintains | Buy → Buy | — | $2.31 | $2.49 | +7.8% | -3.9% | +5.4% | +0.0% | +0.9% | +3.8% |
| Jun 20 | BofA Securities | Downgrade | Neutral → Underperform | — | $2.72 | $2.58 | -5.1% | -15.8% | -3.5% | -1.4% | -4.1% | +4.3% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.41 | $2.44 | +1.2% | -1.2% | -5.5% | -5.3% | -1.4% | +3.3% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.48 | $2.48 | +0.0% | -2.8% | -1.2% | -5.5% | -5.3% | -1.4% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.37 | $2.27 | -4.2% | -13.9% | +2.5% | +4.8% | +1.8% | -2.2% |
| May 7 | Needham | Maintains | Buy → Buy | — | $2.12 | $2.38 | +12.3% | +11.8% | -13.9% | +2.5% | +4.8% | +1.8% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $2.79 | $2.72 | -2.5% | -9.7% | -8.3% | -7.4% | -9.3% | -1.5% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.29 | $2.73 | +19.2% | +14.4% | +3.1% | -3.0% | +2.3% | +4.1% |
| Mar 25 | Needham | Maintains | Buy → Buy | — | $2.29 | $2.73 | +19.2% | +14.4% | +3.1% | -3.0% | +2.3% | +4.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $2.92 | +0.7% | -11.4% | -2.3% | +1.6% | -4.3% | -1.6% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $2.63 | $2.64 | +0.4% | +10.3% | -11.4% | -2.3% | +1.6% | -4.3% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.91 | $0.90 | -0.6% | +4.5% | +15.3% | +5.5% | -3.5% | +7.2% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $0.96 | $1.06 | +10.9% | +7.7% | -3.8% | -10.8% | +2.4% | +4.5% |
| Oct 2 | Needham | Maintains | Buy → Buy | — | $0.98 | $1.00 | +2.0% | -1.0% | -0.3% | -6.3% | +5.9% | +3.1% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.47 | +6.5% | +14.5% | +3.2% | -1.8% | +0.0% | -2.5% |
| Aug 2 | Needham | Maintains | Buy → Buy | — | $1.69 | $1.63 | -3.6% | +5.9% | -8.4% | -0.6% | -2.5% | +1.9% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.40 | +5.3% | +2.3% | +1.5% | +0.0% | -2.9% | +3.7% |
| Jun 15 | BofA Securities | Upgrade | Underperform → Buy | — | $1.23 | $1.39 | +13.0% | +11.4% | +3.6% | +7.7% | -7.2% | +2.1% |
| Jun 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.32 | -2.9% | -2.2% | +2.3% | -0.7% | +1.5% | -0.7% |
| May 9 | Needham | Maintains | Buy → Buy | — | $1.35 | $1.40 | +3.7% | +5.2% | +2.8% | +2.1% | +3.4% | +10.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Halladay BenjaminOff | Chief Financial Officer | Sell | 10,773 | $3.15 | $34K | 702,829 | — | — |
| Jun 17, 2026 | Koenig Sheldon L.Dir/Off | President and CEO | Sell | 53,588 | $3.15 | $169K | 2,119,111 | — | — |
| Jun 17, 2026 | Looker BenjaminOff | Chief Legal Officer | Sell | 11,824 | $3.15 | $37K | 667,524 | — | — |
8-K · 5.02
!!! Very High
Esperion Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 1
8-K
Esperion Therapeutics, Inc. -- 8-K Filing
Esperion Therapeutics shareholders will receive contingent payments up to $100 per share in cash upon achieving specified milestones under a merger agreement, providing potential upside beyond the fixed merger consideration.
May 1
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Esperion Therapeutics spent $180 million on an acquisition, which dilutes shareholder value and raises questions about integration success and ROI that could pressure the stock near-term.
Apr 2
8-K
Unknown — 8-K Filing
Esperion's explosive 144% revenue growth and strategic acquisition of Corstasis to expand its cardiovascular pipeline demonstrates strong execution, justifying continued investor confidence in the company's growth trajectory.
Mar 10
8-K · 1.01
!!! Very High
Esperion Therapeutics, Inc. -- 8-K 1.01: Merger Agreement
Esperion Therapeutics agreed to merge with Corstasis Therapeutics, combining the two cardiovascular drug developers and potentially expanding Esperion's pipeline and market presence.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Wasatch Advisors Lp | 15,768,897 | $43M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 10,433,760 | $29M | New | Mar 2026 |
| 3 | Morgan Stanley | 7,028,454 | $26M | Reduced | Dec 2025 |
| 4 | Two Sigma Investments, Lp | 9,458,779 | $26M | Added | Mar 2026 |
| 5 | Marshall Wace, Llp | 7,075,083 | $19M | Added | Mar 2026 |
| 6 | D.e. Shaw & Co | 6,540,785 | $18M | Reduced | Mar 2026 |
| 7 | Aigh Capital Management Llc | 4,400,000 | $12M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 4,291,711 | $12M | Added | Mar 2026 |
| 9 | Nuveen, Llc | 3,613,709 | $10M | — | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 3,532,563 | $10M | New | Mar 2026 |
| 11 | Privium Fund Management B.v. | 3,299,441 | $9M | New | Mar 2026 |
| 12 | Northern Trust Corp | 2,104,008 | $6M | Added | Mar 2026 |
| 13 | Velan Capital Investment Management Lp | 1,720,000 | $5M | Added | Mar 2026 |
| 14 | Point72 Asset Management | 1,689,372 | $5M | New | Mar 2026 |
| 15 | Renaissance Technologies Llc | 1,620,100 | $4M | Reduced | Mar 2026 |
| 16 | Jane Street Group, Llc | 1,080,736 | $4M | Reduced | Dec 2025 |
| 17 | Barclays Plc | 1,301,911 | $4M | Added | Mar 2026 |
| 18 | Rhenman & Partners Asset Management Ab | 985,000 | $3M | New | Mar 2026 |
| 19 | Susquehanna International Group, Llp | 850,505 | $2M | Reduced | Mar 2026 |
| 20 | Invesco Ltd. | 742,640 | $2M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$654.9M
Enterprise Value
$944.6M
P/E (TTM)
-28.64x
Forward P/E
—
PEG Ratio
0.56x
P/B
—
P/S
1.62x
P/FCF
-50.74x
EV/EBITDA
15.67x
Shares Out
207.9M
Financials (TTM)
Revenue
$403.1M
Net Income
-$22.7M
EBITDA
$60.3M
Free Cash Flow
-$12.9M
Op Cash Flow
-$13.1M
EPS Basic
$-0.11
EPS Diluted
$-0.11
EPS Forward
$-0.01
Gross Margin
68.0%
Op Margin
14.9%
Net Margin
-5.6%
Balance Sheet
Total Assets
$465.9M
Total Liab.
$767.9M
Total Equity
-$302.0M
Cash
$167.9M
LT Debt
$457.6M
Book Value/Sh
$-1.45
Debt/Equity
-1.81x
Current Ratio
0.56
Quick Ratio
0.21
Returns & Growth
ROE
7.5%
ROA
-4.9%
ROIC
23.7%
Rev Growth YoY
+21.3%
EPS Growth YoY
+60.7%
Price Returns
2W
+0.3%
1M
+56.5%
3M
-6.6%
6M
-21.9%
12M
+268.3%
Technicals
52W High
$4.18
52W Low
$0.95
50d MA
$2.78
200d MA
$3.02
RSI (14)
60.00
ATR (14)
$0.01
Beta
1.17
Avg Volume
11.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$9.00
High
$9.00
Low
$9.00
Median
$9.00
Data updated apr 25, 2026 7:44am
· Source: financialmodelingprep.com